Read Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation

Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation

Stephany de Scisciolo

4.9/5 (18508 ratings)

Description:Reducing health disparities by increasing access to health information is a national health policy priority. Evidence exists that direct-to-consumer pharmaceutical advertising (DTCA) is effective in educating consumers about health issues. However, racial disparities exist in such advertising. In 2009, the Food and Drug Administration (FDA) issued a report that included recommendations for enhancing the ability of DTCA to reach disadvantaged populations, including racial and ethnic minorities. This study compares the pharmaceutical advertisements placed in five popular women's magazines published prior to and following the 2009 FDA report to assess the impact of these recommendations on the content and appearance of advertisements placed in magazines of differing racial orientation. This book analyzes 1,090 ads from 237 magazine issues to examine changes in the frequency and types of drugs advertised. A subset of 439 ads were then content analyzed to assess any changes in the appearance and content of the ads. Further analysis addressed the type of appeal (rational versus emotional) used in the ads. From a health policy perspective, the results are disappointing. The FDA recommendations had no impact on the frequency or content of the DTCA appearing in white-oriented versus black-oriented magazines. In fact, far fewer drugs used to treat life-threatening conditions were advertised in black-oriented magazines after the 2009 FDA recommendations. The book concludes that enhancing the educational and motivation value of DTCA will require more than a set of recommendations. The results shed light on the pharmaceutical industry's compliance with both hard and soft regulation. Information that is not required by regulation appeared in less than half of the ads evaluated. Regulation action is necessary to ensure that pharmaceutical companies develop advertising campaigns that not only promote their products, but also positively impact the health outcomes of those who read their ads.We have made it easy for you to find a PDF Ebooks without any digging. And by having access to our ebooks online or by storing it on your computer, you have convenient answers with Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation. To get started finding Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation, you are right to find our website which has a comprehensive collection of manuals listed.
Our library is the biggest of these that have literally hundreds of thousands of different products represented.

Pages: —

Format: PDF, EPUB & Kindle Edition

Publisher: —

Release: —

ISBN: 1498574173

Description: Reducing health disparities by increasing access to health information is a national health policy priority. Evidence exists that direct-to-consumer pharmaceutical advertising (DTCA) is effective in educating consumers about health issues. However, racial disparities exist in such advertising. In 2009, the Food and Drug Administration (FDA) issued a report that included recommendations for enhancing the ability of DTCA to reach disadvantaged populations, including racial and ethnic minorities. This study compares the pharmaceutical advertisements placed in five popular women's magazines published prior to and following the 2009 FDA report to assess the impact of these recommendations on the content and appearance of advertisements placed in magazines of differing racial orientation. This book analyzes 1,090 ads from 237 magazine issues to examine changes in the frequency and types of drugs advertised. A subset of 439 ads were then content analyzed to assess any changes in the appearance and content of the ads. Further analysis addressed the type of appeal (rational versus emotional) used in the ads. From a health policy perspective, the results are disappointing. The FDA recommendations had no impact on the frequency or content of the DTCA appearing in white-oriented versus black-oriented magazines. In fact, far fewer drugs used to treat life-threatening conditions were advertised in black-oriented magazines after the 2009 FDA recommendations. The book concludes that enhancing the educational and motivation value of DTCA will require more than a set of recommendations. The results shed light on the pharmaceutical industry's compliance with both hard and soft regulation. Information that is not required by regulation appeared in less than half of the ads evaluated. Regulation action is necessary to ensure that pharmaceutical companies develop advertising campaigns that not only promote their products, but also positively impact the health outcomes of those who read their ads.We have made it easy for you to find a PDF Ebooks without any digging. And by having access to our ebooks online or by storing it on your computer, you have convenient answers with Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation. To get started finding Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation, you are right to find our website which has a comprehensive collection of manuals listed.
Our library is the biggest of these that have literally hundreds of thousands of different products represented.

Special Offer | $0.00

Special Offer! | $0.00

Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation

Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation

More Books